Healthcare Industry News: proton
News Release - February 6, 2007
Optivus Widens Industry Experience with New Vice President of SalesMichael Martin brings key experience to boost Optivus' national sales efforts
SAN BERNARDINO, Calif., Feb. 6 (HSMN NewsFeed) -- Optivus proton Therapy, Inc., the world leader in proton therapy cancer treatment, has tabbed a former top General Electric Healthcare official to head its aggressive sales expansion as Vice President of Sales, company officials announced Monday.
Michael Martin joins Optivus from General Electric Healthcare where he served in key progressive leadership positions to include General Manager Services, Regional Sales Manager, Corporate Accounts Manager and Service Manager. Mike has a B.S. in Engineering from West Point and a M.A. in Management from Webster University.
"Bringing in an industry seasoned executive as Vice President of Sales will help us increase our presence in the health care marketplace and, in the process, save more lives with our proton therapy technology," said Optivus founding CEO, Jon W. Slater. "Adding new and experienced talent is fundamental to our success and we are gratified with our growing team of skilled people."
Martin has a history of sales accomplishments and has successfully led some of the best teams in the General Electric Company. Most recently, as General Manager and 2005 Omega/Sigma Board member, he was recognized for growing market share and operational margin while achieving unparalleled levels of Customer Satisfaction.
Martin lives in Cincinnati, Ohio with his wife and three children. He will manage Optivus' sales teams in the United States and oversee the company's overall sales expansion.
Contact: Mike Martin, Vice President of Sales, 909-799-8300, firstname.lastname@example.org
A pioneer in the field of proton therapy technology, Optivus proton Therapy, Inc. offers a true turn-key proton Beam Therapy Solution(TM) (PBTS) to institutions committed to bringing the most precise form of radiation therapy to their communities.
FDA cleared for one to seven rooms, Optivus' modular and scalable Conforma 3000® leads the industry in patient throughput, highest operational reliability and demonstrates a perfect safety record after close to a half million individual patient treatments.
For more information about Optivus proton Therapy, Inc., please visit http://www.optivus.com.
Source: Optivus Proton Therapy
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.